stoxline Quote Chart Rank Option Currency Glossary
Rhythm Pharmaceuticals, Inc. (RYTM)
44.37  2.1 (4.97%)    06-13 16:00
Open: 42.22
High: 44.619
Volume: 650,592
Pre. Close: 42.27
Low: 42.19
Market Cap: 2,705(M)
Technical analysis
2024-06-13 4:46:05 PM
Short term     
Mid term     
Targets 6-month :  52.11 1-year :  60.87
Resists First :  44.61 Second :  52.11
Pivot price 38.79
Supports First :  38.77 Second :  35.16
MAs MA(5) :  41.54 MA(20) :  38.69
MA(100) :  41.8 MA(250) :  33.39
MACD MACD :  0.7 Signal :  -0.1
%K %D K(14,3) :  90 D(3) :  90.2
RSI RSI(14): 67.3
52-week High :  52.56 Low :  15.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RYTM ] has closed Bollinger Bands are 39.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 44.67 - 44.84 44.84 - 44.97
Low: 41.76 - 41.96 41.96 - 42.12
Close: 44.05 - 44.38 44.38 - 44.64
Company Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headline News

Thu, 13 Jun 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Up 4.3% - MarketBeat

Thu, 13 Jun 2024
The one-year returns have been splendid for Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders despite underlying losses increasing - Simply Wall St

Wed, 12 Jun 2024
Commodore Capital LP Trims Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Wed, 12 Jun 2024
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments - Seeking Alpha

Tue, 11 Jun 2024
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire

Mon, 10 Jun 2024
Campbell & CO Investment Adviser LLC Acquires Shares of 10742 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 61 (M)
Shares Float 46 (M)
Held by Insiders 0.5 (%)
Held by Institutions 116 (%)
Shares Short 10,320 (K)
Shares Short P.Month 10,200 (K)
Stock Financials
EPS -4.64
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin -298 %
Operating Margin -538.8 %
Return on Assets (ttm) -56.3 %
Return on Equity (ttm) -194.7 %
Qtrly Rev. Growth 126.4 %
Gross Profit (p.s.) 0
Sales Per Share 1.5
EBITDA (p.s.) -4.43
Qtrly Earnings Growth 0 %
Operating Cash Flow -140 (M)
Levered Free Cash Flow -188 (M)
Stock Valuations
PE Ratio -9.59
PEG Ratio 0.9
Price to Book value 43.93
Price to Sales 29.42
Price to Cash Flow -19.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android